NLRP3 and autoimmune disease: Therefore, small-molecule inhibitors of palmitoyl-acyltransferase ZDHHC7 or directly targeting NLRP3 Cys126 residue can potentially suppress inflammasome activation and thus may be useful for treating inflammation and autoimmune diseases.